Ockham Development Group, an ASG Company, and etrials Worldwide Announce 5-year EDC Technology Transfer Agreement

etrials Worldwide, Inc. (Nasdaq: ETWC), a leading provider of adaptive eClinical solutions, and Ockham Development Group -- a global contract research and development organization and wholly owned subsidiary of ASG, Inc. -- today announced they have entered into a five-year technology transfer agreement, which enables Ockham Development Group to provide its global customers with etrials� Trial Intelligence electronic data capture (EDC) solutions.

Under etrials� CRO Partnership Solutions program, the five-year in-licensing agreement allows ASG�s Ockham Development Group (Ockham) to offer its sponsor customers a more comprehensive suite of eClinical capabilities for aggregating, monitoring and analyzing data with the ability to develop and deploy studies on their own.

Under the agreement, Ockham will be self-sufficient in terms of developing and deploying studies using etrials� EDC solutions, and etrials will provide best practices, training, hosting, development, technical, as well as sales and marketing support.

�This joint venture further allows ASG and Ockham to expand our service capabilities and better serve sponsors,� said Ockham President Dr. Joshua S. Baker, who leads clinical operations for the group. �The addition of etrials� adaptive solutions to Ockham�s offering portfolio increases our ability to provide an even greater breadth of integrated solutions with a highly flexible, robust EDC system delivered directly from us.�

�This agreement gives ASG and Ockham the opportunity to transfer etrials� knowledge of EDC design and deployment best practices and support and meet their sponsors� clinical trial development requirements more holistically,� said Denis Connaghan, etrials� President and Chief Executive Officer. �At the same time, etrials� EDC solution will serve a wider sponsor base.�

About etrials(R)

Headquartered near North Carolina�s Research Triangle Park, etrials Worldwide, Inc. (Nasdaq: ETWC), is a leading provider of eClinical software and services to pharmaceutical, biotechnology, and medical device companies, as well as contract research organizations, offering adaptive, Web-based tools that work together to coordinate data capture, logistics, patient interaction and trial management � turning data into intelligence and shortening the pathway to an actionable study endpoint. etrials is one of the few top-tier solution providers that offers electronic data capture (EDC), interactive voice and Web response (IVR/IWR) and electronic patient diaries (eDiary), as part of a flexible and integrated software-as-a-service (SaaS) platform or as individual solutions to capture high quality data from multiple pivot points to enable real-time access for informed decision-making. As an experienced leader, etrials has facilitated over 900 trials involving more than 400,000 patients in 70 countries and has participated in 42 studies that resulted in 14 approved new drug applications and/or regulatory approvals. To learn more, visit us at www.etrials.com. etwcf

About ASG

ASG is a global clinical research service provider of high-quality Contract Research, Functional Outsourcing, and Specialty Staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. Strategically organized to meet the demands of the marketplace, ASG provides flexible solutions that satisfy client needs through highly experienced recruiting and dedicated functional support teams located throughout the world. Staffed by veteran industry professionals with a track record of proven results, it is centrally located near the university-technology-biotech/pharmaceutical sciences nexus known internationally as Research Triangle Park (RTP).

About Ockham Development Group

Ockham Development Group, a wholly owned subsidiary of ASG, is a privately held contract drug development company headquartered in Cary, North Carolina.

Forward-Looking Statements

This announcement may contain forward-looking statements, including statements regarding the size, number of sites and patients, new projects, modifications to existing projects, and duration of clinical trial projects awarded to the Company. These statements involve risks and uncertainties. Actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to, the need to finalize definitive agreements for the awards, delays in the current schedule for clinical trials by the client, utilization of our software and services by clients to a lesser degree than is currently expected and early termination of the projects, all of which are possible because our agreements do not generally have minimum volume guarantees and can be terminated without penalty by clients. More information about potential factors which could cause actual results to differ from the forward-looking statements included in this announcement is included in our filings with the Securities and Exchange Commission, including the "Risk Factors" Section of the Form 10-K filed on March 10, 2009. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update such statements.

etrials� is the registered trademark in the United States of etrials Worldwide, Inc. Other marks belong to their respective owners and are used with permission.

Etrials Worldwide (MM) (NASDAQ:ETWC)
Historical Stock Chart
From Apr 2024 to May 2024